September 2004
Basiliximab Plus Tacrolimus Reduce Liver Transplant Rejection, Increase Survival
(Published 9-24-2004) Basiliximab in a tacrolimus-based immunosuppressive regimen is effective in reducing incidences of acute
cellular rejection (ACR) and improving ACR-free survival after orthotopic liver transplantation (OLTx), without increasing
the incidence of adverse events or infections, according to the results of a prospective study published in the Sept. 27 issue
of Transplantation, posted online Sept. 22.